期刊文献+

地尔硫缓释胶囊联合氯沙坦治疗慢性肾功能不全并发高血压的疗效 被引量:3

Efficacy of Diltiazem Sustained-release Capsules Combined with Losartan on Chronic Renal Insufficiency and Hypertension
下载PDF
导出
摘要 目的观察地尔硫缓释胶囊联合氯沙坦治疗慢性肾功能不全并发高血压患者的临床疗效。方法将84例慢性肾功能不全并发高血压患者按随机数字表法分为2组。治疗组43例,采用地尔硫90 mg.次-1,2次.d-1;加氯沙坦50 mg,1次.d-1。对照组41例,给予氯沙坦50 mg,1次.d-1。2组均治疗观察6个月,对2组高血压、心率及血清肌酐水平变化进行比较。结果 2组治疗后的血压均较治疗前明显降低(均P<0.05)。治疗组治疗后心率及血清肌酐水平较治疗前明显下降(均P<0.05),对照组治疗前后心率及血清肌酐水平比较差异均无统计学意义(均P>0.05)。治疗组治疗高血压总有效率为93.02%,对照组总有效率为73.17%,2组比较差异有统计学意义(P<0.05)。结论地尔硫缓释胶囊联合氯沙坦治疗慢性肾功能不全并高血压较单用氯沙坦能更显著地降低患者的血压,且无明显的不良反应,有效地延缓患者的血清肌酐水平的升高。 Objective To observe the efficacy of diltiazem sustained-release capsules combined with losartan in patients with chronic renal failure and hypertension.Methods Eighty-four patients with chronic renal failure and hypertensive were randomly treated with losartan 50 mg once daily alone(control group,n=41)or in combination with diltiazem 90 mg twice daily(treatment group,n=43)for 6 months.The changes in blood pressure,heart rate and serum creatinine level were compared between the two groups.Results After treatment,blood pressure significantly decreased in both groups(P0.05).In addition,heart rate and serum creatinine level obviously reduced in treatment group(P0.05),but did not significantly change in control group(P0.05).The total effective rate in treatment group was significantly higher than that in control group(93.02% vs 73.17%,P0.05).Conclusion The combined treatment with diltiazem sustained-release capsules and losartan can lower blood pressure and delay the increase in serum creatinine with no adverse reactions in patients with chronic renal failure and hypertension.
作者 陈勇鹏
出处 《实用临床医学(江西)》 CAS 2012年第5期6-8,共3页 Practical Clinical Medicine
关键词 慢性肾功能不全并发高血压 血清肌酐水平 地尔硫缓释胶囊 氯沙坦 chronic renal insufficiency complicated by hypertension serum creatinine diltiazem sustained release capsules losartan
  • 相关文献

参考文献3

二级参考文献30

  • 1Leonetti G ,Cuspidi C .Choosing the right ACE inhibitor :A guide to selection[J] .Drugs ,1995,45:516 -535.
  • 2Anon.Effects of an angiotensin-converting enzyme inhibitor ,ramipril ,on cardio-Vascular events in high-risk patients [J] .N Engl J Med,2003,342 (3):145 - 153.
  • 3Lorell BH.Role of angiotensin AT1,and AT2 receptors in cardiac hypertrophy and disease[J].Am J Cardiol ,1999,83(12A):48H -52H.
  • 4Mazzolai C ,Burnier M.Comparative safety and tolerability of angiotensin Ⅱ receptor antagonists [J].Drug Saf,1999,21:23 - 33.
  • 5Goodfriend TL,Elliott ME Catt KJ.Drug therapy.Angiotensin receptors and their antagonists [J].N Eng T Med,1996,334:1649 -1654.
  • 6Messerli FH ,Weber MA ,Brunner HR.Angiotension Ⅱ reeeptor inhibitor[J].Arch Intern Med,1996,156:1957 - 1965.
  • 7Mazzolai:L ,Maillard M,Rossat J,et al.Angiotensin Ⅱ receptor blockade in normotensive subjects .A direct comparison of three AT1.Receptor antagonists [J].Hypertension,1999,33:850 - 855.
  • 8Michel Burnier ,Mare Maillard.The comparative pharmacology of Angiotensin Ⅱ receptor antagonists [J].Blood pressure,2001,10(suppl 1):6-11.
  • 9Burnier M ,Hayman M ,Nussberger J ,et al .Short-term and sustained renal effects of angiotension Ⅱ receptor blockade in healthy subjects[J] .Hypertension,1995,25:602 -609.
  • 10Coreal ,Cardoni 0 ,Fogari R,et al.Valsartan.A new angiotension Ⅱ antagonist for the treatment of essential hypertension :a comparative study of the efficacy and safety against amlodipine[J].Clin pharmacol Ther,1996,60:34 - 346.

共引文献14

同被引文献24

引证文献3

二级引证文献18

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部